{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-130482","form_type":"8-K","ticker":"NRXP","cik":"0001719406","company_name":"NRX Pharmaceuticals, Inc.","filed_at":"2023-12-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.173524+00:00","generated_at":"2026-06-07T05:56:47.017753+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"NRx Pharmaceuticals shareholders approve share increase, elect director at 2023 annual meeting","bullets":["Elected Janet Rehnquist as Class II director: 43.7M votes for, 0.5M withheld.","Approved amendment to 2021 Omnibus Plan: share pool raised from 6,713,608 to 8,713,608 shares; 29.7M for, 13.5M against.","Ratified Salberg & Company as independent auditor for FY2023: 42.1M for, 1.9M against.","Advisory 'say-on-pay' approved (32.0M for, 11.4M against); board set future advisory votes on exec compensation to annual."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-130482","json":"https://secwatch.observer/filing/0001104659-23-130482.json","markdown":"https://secwatch.observer/filing/0001104659-23-130482.md","text":"https://secwatch.observer/filing/0001104659-23-130482.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719406/000110465923130482/0001104659-23-130482-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719406/000110465923130482/tm2333890d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T05:56:47.017753+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4e1e89ab8dabb93037abfcb2df729e8e055edd70","claim":"NRX Pharmaceuticals, Inc. shareholders approved Advisory vote on frequency of future advisory votes on executive compensation.","evidence_excerpt":"The Company’s stockholders approved, on an advisory basis, the frequency of holding an advisory vote on executive compensation.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1719406/000110465923130482/0001104659-23-130482-index.htm","confidence":0.7,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"519767883eecd72b6fd919166c54aa0b087ac40e","claim":"NRX Pharmaceuticals, Inc. shareholders approved Advisory vote on compensation of named executive officers.","evidence_excerpt":"The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as set forth in the Proxy Statement.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1719406/000110465923130482/0001104659-23-130482-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"5b2214d0e8a05c490fc978273f333e02f36285e1","claim":"NRX Pharmaceuticals, Inc. shareholders approved Approval of the Plan Amendment.","evidence_excerpt":"The Company’s stockholders approved the Plan Amendment.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1719406/000110465923130482/0001104659-23-130482-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"b6232d4125114b395aa107e184ec860bba61fd42","claim":"NRX Pharmaceuticals, Inc. shareholders approved Ratification of Salberg & Company, P.A. as independent auditors for fiscal year 2023 at the 2023-12-31 meeting.","evidence_excerpt":"The Company’s stockholders ratified the selection of Salberg & Company, P.A. as the Company’s independent auditors for the fiscal year ending December 31, 2023.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1719406/000110465923130482/0001104659-23-130482-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-12-31"}],"fact_type":"shareholder_vote"},{"claim_id":"d95ff4a79880030306d767e527affc9a1e9d5ad1","claim":"NRX Pharmaceuticals, Inc. shareholders approved Election of Janet Rehnquist as a Class II director.","evidence_excerpt":"The Company’s stockholders duly elected Janet Rehnquist to serve as a Class II member of the Company’s board of directors until the 2026 Annual Meeting or until the appointment, election, and qualification of her successor.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1719406/000110465923130482/0001104659-23-130482-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}